Last updated: 18 June 2024 at 5:06pm EST

James Caruso Net Worth




The estimated Net Worth of James V Caruso is at least $1.2 million dollars as of 4 March 2021. Mr. Caruso owns over 5,100 units of Cellectar Biosciences Inc stock worth over $180,578 and over the last 9 years he sold CLRB stock worth over $81,600. In addition, he makes $934,460 as President, Chief Executive Officer et Director at Cellectar Biosciences Inc.

Mr. Caruso CLRB stock SEC Form 4 insiders trading

James has made over 11 trades of the Cellectar Biosciences Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he bought 5,100 units of CLRB stock worth $8,670 on 4 March 2021.

The largest trade he's ever made was buying 46,948 units of Cellectar Biosciences Inc stock on 20 April 2016 worth over $99,530. On average, James trades about 8,492 units every 88 days since 2015. As of 4 March 2021 he still owns at least 86,401 units of Cellectar Biosciences Inc stock.

You can see the complete history of Mr. Caruso stock trades at the bottom of the page.





James Caruso biography

James V. Caruso serves as President, Chief Executive Officer, Director of the Company. Mr. Caruso was appointed our President and Chief Executive Officer and a director in June 2015. He came to Cellectar from Hip Innovation Technology, a medical device company where he was a founder and served as Executive Vice President and Chief Operating Officer from August 2010 to June 2015, and he currently serves on their board. Prior to his time at Hip Innovation Technology, he was Executive Vice President and Chief Commercial Officer of Allos Therapeutics, Inc., an oncology company acquired by Spectrum Pharmaceuticals, from June 2006 to August 2010. He was also Senior Vice President, Sales and Marketing, from June 2002 to May 2005, at Bone Care International, Inc., a specialty pharmaceutical company that was acquired by Genzyme Corporation. In addition, Mr. Caruso has held key positions at several well-known pharmaceutical companies, including Novartis, where he was Vice President of Neuroscience Specialty Sales, BASF Pharmaceuticals-Knoll, where he was Vice President, Sales, and Bristol-Myers Squibb Company in several senior roles. Mr. Caruso earned a Bachelor of Science degree in Finance from the University of Nevada. Mr. Caruso’s extensive experience in the biotechnology industry and his recent experience as our Chief Executive Officer make him a highly qualified member of our Board of Directors.

What is the salary of James Caruso?

As the President, Chief Executive Officer et Director of Cellectar Biosciences Inc, the total compensation of James Caruso at Cellectar Biosciences Inc is $934,460. There are no executives at Cellectar Biosciences Inc getting paid more.



How old is James Caruso?

James Caruso is 61, he's been the President, Chief Executive Officer et Director of Cellectar Biosciences Inc since 2015. There are 4 older and 7 younger executives at Cellectar Biosciences Inc. The oldest executive at Cellectar Biosciences Inc is Frederick Driscoll, 69, who is the Independent Director.

What's James Caruso's mailing address?

James's mailing address filed with the SEC is C/O CELLECTAR BIOSCIENCES, INC., 100 CAMPUS DRIVE, FLORHAM PARK, NJ, 07932.

Insiders trading at Cellectar Biosciences Inc

Over the last 10 years, insiders at Cellectar Biosciences Inc have traded over $1,263,511 worth of Cellectar Biosciences Inc stock and bought 1,917,793 units worth $3,966,598 . The most active insiders traders include Austin W & Greenhouse David..., Investment Company, Inc. Awm et John Neis. On average, Cellectar Biosciences Inc executives and independent directors trade stock every 50 days with the average trade being worth of $126,821. The most recent stock trade was executed by Douglas J Swirsky on 14 September 2021, trading 25,000 units of CLRB stock currently worth $26,000.



What does Cellectar Biosciences Inc do?

cellectar biosciences is developing phospholipid drug conjugates (pdcs) designed to provide cancer targeted delivery of diverse oncologic payloads to a broad range of cancers and cancer stem cells. cellectar's pdc platform is based on the company's proprietary phospholipid ether analogs. these novel small-molecules have demonstrated highly selective uptake and retention in a broad range of cancers. cellectar's pdc pipeline includes product candidates for cancer therapy and cancer diagnostic imaging. the company's lead therapeutic pdc, clr 131, utilizes iodine-131, a cytotoxic radioisotope, as its payload. clr 131 has been designated as an orphan drug by the us fda and is currently being evaluated in a phase 1 clinical study in patients with relapsed or refractory multiple myeloma and a phase 2 clinical study to assess efficacy in a range of b-cell malignancies. the company is also developing proprietary pdcs for targeted delivery of chemotherapeutics and has several preclinical stage p



What does Cellectar Biosciences Inc's logo look like?

Cellectar Biosciences Inc logo

Complete history of Mr. Caruso stock trades at Cellectar Biosciences Inc

Date
#
Société
Initié
Trans.
Transaction
Actions Prix par action Prix ​​total Actions après Source
4 Mar 2021 James V Caruso
Président et PDG
Acheter 5,100 $1.70 $8,670
4 Mar 2021
86,401
28 Dec 2020 James V Caruso
Président et PDG
Acheter 37,037 $1.35 $50,000
28 Dec 2020
81,301
5 Jun 2020 James V Caruso
Président et PDG
Acheter 21,740 $1.15 $25,001
5 Jun 2020
44,264
30 Nov 2018 James V Caruso
Président et PDG
Acheter 1,000 $2.28 $2,280
30 Nov 2018
22,354
12 Mar 2018 James V Caruso
Président et PDG
Vente 34,000 $1.20 $40,800
12 Mar 2018
213,548
20 Apr 2016 James V Caruso
Président et PDG
Acheter 46,948 $2.12 $99,530
20 Apr 2016
47,548
24 Nov 2015 James V Caruso
Président et PDG
Acheter 1,000 $1.30 $1,300
24 Nov 2015
6,000
20 Nov 2015 James V Caruso
Président et PDG
Acheter 1,000 $1.16 $1,160
20 Nov 2015
5,000
18 Nov 2015 James V Caruso
Président et PDG
Acheter 4,000 $1.45 $5,800
18 Nov 2015
4,000


Cellectar Biosciences Inc executives and stock owners

Cellectar Biosciences Inc executives and other stock owners filed with the SEC include: